Reported Earnings • Mar 05
First half 2026 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2025) First half 2026 results: AU$0.003 loss per share (in line with 1H 2025). Revenue: AU$2.62m (down 53% from 1H 2025). Net loss: AU$11.2m (loss widened 293% from 1H 2025). New Risk • Mar 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$8.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.5m free cash flow). Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-AU$3.0m). Shareholders have been substantially diluted in the past year (177% increase in shares outstanding). Market cap is less than US$10m (AU$6.63m market cap, or US$4.72m). Annonce • Dec 23
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 776,567,389
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 690,099,278
Price\Range: AUD 0.003
Discount Per Security: AUD 0.00018
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annonce • Oct 27
Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025 Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australia Annonce • Oct 10
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 164,307,917
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,092,679,329
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 387,577,500
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,435,254
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Transaction Features: Subsequent Direct Listing New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.3m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 1.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (264% increase in shares outstanding). Market cap is less than US$10m (AU$9.76m market cap, or US$6.39m). Minor Risk Revenue is less than US$5m (AU$4.0m revenue, or US$2.6m). Annonce • May 20
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 164,300,000
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,485,700,000
Price\Range: AUD 0.004
Discount Per Security: AUD 0.00024
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annonce • Apr 24
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 197,203,052
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0001
Transaction Features: Rights Offering Annonce • Mar 04
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 638,059,938
Price\Range: AUD 0.005
Discount Per Security: AUD 0.0003
Transaction Features: Rights Offering New Risk • Mar 01
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: AU$1.1m (US$710k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Revenue is less than US$1m (AU$1.1m revenue, or US$710k). Market cap is less than US$10m (AU$10.2m market cap, or US$6.35m). Annonce • Feb 13
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.005
Transaction Features: Subsequent Direct Listing New Risk • Feb 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 87% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (87% increase in shares outstanding). Market cap is less than US$10m (AU$9.45m market cap, or US$5.84m). Minor Risk Revenue is less than US$5m (AU$7.5m revenue, or US$4.6m). New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 37% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Market cap is less than US$10m (AU$5.97m market cap, or US$3.72m). Minor Risk Revenue is less than US$5m (AU$7.5m revenue, or US$4.6m). Annonce • Dec 09
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 69,990,973
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 430,009,027
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Annonce • Oct 23
Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 69,990,973
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 430,009,027
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 125,000,000
Price\Range: AUD 0.008
Discount Per Security: AUD 0.00048
Transaction Features: Subsequent Direct Listing Annonce • Oct 14
Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024 Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australia New Risk • Aug 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year). Market cap is less than US$100m (AU$17.7m market cap, or US$11.5m). New Risk • Jun 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Market cap is less than US$10m (AU$14.7m market cap, or US$9.74m). Minor Risk Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year). New Risk • May 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 42% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$18.8m market cap, or US$12.4m). New Risk • Mar 01
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$21.9m market cap, or US$14.3m). Annonce • Jan 18
Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 273,717,042
Price\Range: AUD 0.028
Transaction Features: Rights Offering New Risk • Dec 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Revenue is less than US$5m (AU$4.5m revenue, or US$3.0m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.1m). Annonce • Nov 01
Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101 Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024. New Risk • Oct 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$16m free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$4.5m revenue, or US$2.9m). Market cap is less than US$100m (AU$21.9m market cap, or US$13.9m). Annonce • Oct 16
Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023 Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters. Price Target Changed • Sep 07
Price target decreased by 14% to AU$0.60 Down from AU$0.70, the current price target is provided by 1 analyst. New target price is 1,718% above last closing price of AU$0.033. Stock is down 69% over the past year. The company posted a net loss per share of AU$0.059 last year. New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (AU$49m net loss in 3 years). Shareholders have been diluted in the past year (24% increase in shares outstanding). Revenue is less than US$5m (AU$5.7m revenue, or US$3.7m). Market cap is less than US$100m (AU$19.6m market cap, or US$12.7m). Annonce • Aug 30
Chimeric Therapeutics Limited Announces Board Changes Chimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors. Annonce • Aug 03
Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director Chimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company. Annonce • Jul 12
Chimeric Therapeutics Limited Announces Board Changes Chimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution". Annonce • Jun 05
Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical Trial Chimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial. Annonce • Jan 24
Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 Trial Chimeric Therapeutics provided an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center's phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose- limiting toxicities. Patients in the 3rd dose cohort received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cellsthrough dual routes of intratumoral (ICT) and intraventricular (ICV) administration. Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440 X 106 CHM 1101 CAR T cells by ICT and ICV administration. City of Hope, one of the larger cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent /progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma. CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours. CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers. Annonce • Jan 20
Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib Trial Chimeric Therapeutics, announced that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication. The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics. Annonce • Dec 23
Chimeric Therapeutics Limited Completes Dosing in Third Cohort of CHM 1101 (CLTX CAR T) Trial Chimeric Therapeutics announced the successful completion of the planned dosing of the third patient cohort (n=3) in the Phase 1 dose escalation study evaluating the safety and maximum tolerated dose of Chimeric's CHM 1101 (CLTX CAR T) cell therapy, in patients with recurrent or progressive glioblastoma (GBM). The Phase 1A CHM 1101 clinical trial is taking place at City of Hope, one of the largest cancer research and treatment organizations in the United States. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. Behnam Badie, M.D., City of Hope Chief of Division of Neurosurgery, is the trial's principal investigator. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across 4 dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a Phase 2 trial. Patients (n=3) in this third dose level received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cells through dual routes of intratumoral and intraventricular administration. Once the final evaluable patient of this third dose cohort successfully completes the 28 DLT period, the study will be able to advance to recruitment of patients at the fourth and final planned dose level of 440 X 106 CHM 1101 (CLTX CAR T) cells through dual routes of administration (intratumoral and intracranial intraventricular). CHM 1101, Chimeric's Chlorotoxin CAR T (CLTX CAR T) is a first in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent/progressive glioblastoma. CHM 1101 uniquely utilizes chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR) which has been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells/tissues, supporting a potentially optimal safety and efficacy profile. Price Target Changed • Dec 02
Price target decreased to AU$0.71 Down from AU$0.94, the current price target is provided by 1 analyst. New target price is 745% above last closing price of AU$0.084. Stock is down 68% over the past year. The company is forecast to post a net loss per share of AU$0.06 next year compared to a net loss per share of AU$0.044 last year. Board Change • Nov 16
No independent directors There are 9 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Founder & Executive Chairman Paul Hopper is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Annonce • Oct 15
Chimeric Therapeutics Limited, Annual General Meeting, Nov 15, 2022 Chimeric Therapeutics Limited, Annual General Meeting, Nov 15, 2022, at 10:00 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2022; to consider the remuneration report; to consider the re-election of Director Mr. Paul Hopper; to consider the renewal of Omnibus Incentive Plan; to consider the 10% capacity to issue shares under Listing Rule 7.1A; to consider the issue of options to Director Ms. Jennifer Chow; to consider the issue of Shares to Director Ms. Jennifer Chow; and to consider the other matters. Annonce • Jul 25
Chimeric Therapeutics Limited Appoints Jason B. Litten as Chief Medical Officer Chimeric Therapeutics has appointed Dr. Jason B. Litten, to the position of Chief Medical Officer (CMO). Dr. Litten brings almost 15 years of leadership in drug development with the past five years dedicated to advancing NK and CAR T cell therapy clinical-stage programs in oncology. Entering the cellular immunotherapy field in early days, Dr. Litten has been part of the foundational clinical understanding of cell therapies, working on numerous CAR T and NK cell drug candidates. Most recently, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics where he led the development of a portfolio of allogeneic Natural Killer (NK) cell therapies. Prior to Artiva, Dr. Litten was Vice President Clinical Development at Juno Therapeutics where he built and oversaw the autologous solid tumour CAR T and TCRs cell therapy programs. In addition to the key roles Dr. Litten has held at cell therapy companies Artiva and Juno, Dr. Litten was also previously a Vice President Clinical Development at Clovis Oncology and prior to that a Medical Director on the Oncology Clinical Development Team at Amgen. Dr. Litten earned his MD at Emory University, completed an internship and residency in General Pediatrics at the University of Miami and a fellowship in Pediatric Oncology at The University of Texas Southwestern. Annonce • Jun 24
Chimeric Therapeutics Announces First Ever Phase 1B Trial of NK Cells with IL-2 & Vactosertib Chimeric Therapeutics announced that the first ever trial studying NK cells is combination with IL-2 and Vactosertib is being undertaken with Chimeric's CORE NK platform cells. The phase 1B investigator-initiated trial has received approval by the U.S. Food and Drug Administration and once initiated will look to enroll 12 patients at UH Seidman Cancer Center in Ohio with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. Chimeric's CORE NK platform is a novel NK cell therapy platform of ex-vivo expanded non-HLA-matched universal donor NK cells. The CORE NK platform was previously studied in a phase 1A clinical trial that demonstrated safety and an early efficacy signal in patients with metastatic colorectal cancer and refractory hematological malignancies. This new study seeks to build upon the responses seen in the initial CORE NK clinical trial by co-administering the CORE NK cells with subcutaneous IL-2 and oral Vactosertib. IL-2 is known to activate NK cells by stimulating proliferation and enhancing function. Vactosertib is an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway, which has been shown to limit the effectiveness of immune therapies like NK cells. Annonce • Jun 11
Chimeric Therapeutics Announces the Completion of Manufacturing and Quality Release for CHM 1101 (CLTX CAR T) Viral Vector, a Key Milestone in its Development Chimeric Therapeutics announced the completion of manufacturing and quality release for CHM 1101 (CLTX CAR T) viral vector, a key milestone in its development. The viral vector was developed and manufactured at City of Hope, a world-renowned cancer research and treatment organization near Los Angeles. Chimeric is currently focused on expanding the CHM 1101 (CLTX CAR T) clinical program with new clinical sites for the Phase 1 glioblastoma trial as well as a new Phase 1 clinical basket trial in solid tumours. This broadened clinical development program requires coordinated expansion of Chimeric's current technical operations. One of the most challenging and critical components of cell therapy technical operations is the timely manufacturing and release of viral vector. Viral vector is considered the backbone for the manufacture of a CAR T cell therapy as it holds the genetic engineering instructions. A current shortage of vector manufacturing capacity has significantly delayed other cell therapy company development programs, as well as challenging commercial manufacturers. Given these difficulties this is a critical milestone for Chimeric in supporting the broader Phase 1 clinical program expansion of CHM 1101 (CLTX CAR T). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Cellular Immunotherapy Scientific Advisory Board Eric Smith was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Feb 08
Chimeric Therapeutics Limited Announces Encouraging Data from 2Nd Dose Cohort in CLTX CAR T trial Chimeric Therapeutics reported encouraging initial data for the 2nd dose cohort of the CLTX CAR T phase 1 dose escalation study for patients with recurrent/progressive glioblastoma at the City of Hope®, one of the cancer research and treatment organizations in the United States. In the 2nd dose cohort, dual routes of intratumoral and intraventricular CLTX CAR T cell administration were introduced at a total dose of 88 X 106 CLTX CAR T cells. City of Hope developed and manufactured the therapy. Positive initial safety was seen as patients generally well tolerated the dual routes (intratumoral and intraventricular) of CLTX CAR T cell administration introduced in this dose cohort. As previously announced, all patients advanced past the 28-day follow-up without experiencing dose limiting toxicities. Additionally, an encouraging activity signal was demonstrated with 2/3 evaluable patients treated achieving local stability of disease. Additional insights into this cohort are anticipated to be presented at a scientific congress as the trial progresses. The study is now enrolling patients in the 3rd dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an increased total dose of 220 X 106 CLTX CAR T cells. Annonce • Dec 19
Chimeric Therapeutics Limited Successful Completion of 2nd Dose Cohort in CLTX CAR T Trial Chimeric Therapeutics announced the successful completion of the 2nd dose cohort in the CLTX CAR T phase 1 dose escalation study at the City of Hope, a world-renowned cancer research and treatment organization near Los Angeles. All patients in the 2nd dose cohort were dosed with a total dose of 88 X 106 CLTX CAR T cells (double that used in the first dose cohort) and have now advanced past the 28 day follow up period without experiencing any dose limiting toxicities. The successful completion of this 2nd patient cohort is a significant milestone for CLTX CAR T cell therapy as the 2nd dose cohort introduced dual routes (intraventricular and intratumoral) of CLTX CAR T administration. The study now advances to the 3rd dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an increased total dose of 220 X 106 CLTX CAR T cells. Recent Insider Transactions • Dec 12
Executive Chairman recently bought AU$98k worth of stock On the 3rd of December, Paul Hopper bought around 375k shares on-market at roughly AU$0.26 per share. This was the largest purchase by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months. Annonce • Nov 24
Chimeric Therapeutics Limited Highlights Key Additional Data Released with the Final Presentation of Two CLTX Car T Abstracts At the Society for Neuro-Oncology 26th Annual Scientific Meeting Chimeric Therapeutics Limited highlighted key additional data released with the final presentation of two CLTX CAR T abstracts at the Society for Neuro-Oncology (SNO) 26th annual scientific meeting. The clinical data presented in abstract CTIM-29 is from the ongoing CLTX CAR T phase 1 clinical trial in patients with MMP2+ recurrent or progressive glioblastoma. The data focuses on the four patients enrolled in dose level 1 of the trial, treated with 44 X 106 CLTX CAR T cells through a single route of intratumoral administration. Dose escalation in this trial is planned across four dose levels to a total dose of 440 X 106 CLTX CAR T cells administered through dual intratumoral and intraventricular routes of administration Of significant note, during the final presentation MRI scans presented of patient 487 demonstrated no recurrence of tumour in the left frontal lobe where CLTX CAR T cells were infused, two months after the CLTX CAR T cell infusion. Tumour progression was seen only in the left temporal lobe which did not receive CLTX CAR T infusion. Like all patients in this dose level, patient 487 received a dose of 44 X 10 CLTX CAR T cells through a single intratumoral route of administration. This finding, that tumour recurrence was prevented in the area where the CLTX CAR T cells were infused and tumour progression occurred in areas away from where the CLTX CAR T cells were infused, is important as it suggests that the dual routes of administration (intratumoral and intraventricular) of the CLTX CAR T cells in dose levels 2-4 may provide additional hope for patients. In the initial abstract presentation of patients treated at the 1st dose level, a disease control rate of 75% was shown as 3 out of the 4 patients treated achieved a best response of stable disease assessed by RANO criteria. Additional details provided within the final presentation demonstrated that the disease control observed was durable for approximately 5-8 weeks. The final presentation of the CLTX CAR T CTIM-29 abstract also provided additional insight into the generally well tolerated adverse event profile of CLTX CAR T, showing that there were no CRS events, an adverse event often associated with CAR T cell therapy. Confirmation that the one grade 3 cerebral edema event was only possibly attributed to the CAR T cells was also presented. Cerebral edema is an adverse event commonly observed in patients with glioblastoma. In addition, the presentation of abstract EXTH-10 provided early confirmation of the role of MMP-2 expression in CLTX CAR T tumour recognition and killing. Data presented showed that MMP-2 expression levels increased with tumour grade and that CLTX CART T cells preferentially kill tumour target cells with higher MMP-2 expression, suggesting that CLTX CAR T may be effective even against the most aggressive cancers. Within the presentation, early staining of a melanoma cell line was also presented confirming strong MMP-2 expression and providing early support for expanding the clinical development program for CLTX CAR T into additional solid tumours, including melanoma. Recent Insider Transactions • Aug 10
Non-Executive Director recently bought AU$166k worth of stock On the 4th of August, George Matcham bought around 500k shares on-market at roughly AU$0.33 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$178k more in shares than they have sold in the last 12 months. Annonce • May 24
Chimeric Therapeutics Announces Initiation of Second Dose Cohort Chimeric Therapeutics announced the treatment of the first patient in the second dose cohort in City of Hope's phase 1 clinical trial evaluating the safety and tolerability of Chimeric's chlorotoxin CAR T (CLTX CAR T) cell therapy. The treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing. This second dose cohort will receive a total target dose of 88 × 106 CLTX CAR T cells. City of Hope's phase 1 clinical trial is expected to enroll 18-36 patients with MMP2+ progressive or recurrent glioblastoma over a 24- month period. Annonce • Mar 18
Chimeric Therapeutics Limited Announces Successful Completion of Dosing in First Patient Cohort Chimeric Therapeutics announced the successful completion of the planned dosing of the first patient cohort (n=4) in the phase 1 dose escalation study, evaluating the safety and maximum tolerated dose of Chimeric's Chlorotoxin CAR T (CLTX CAR T) in patients with recurrent or progressive glioblastoma (GBM). The Phase 1 study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across 4 dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. The dosing of this 4th patient marks the completion of planned dosing in the first and lowest dose level. Patients in this dose cohort were dosed via single site administration (intracranial intratumoral or intracavitary (ICT) administration). As this is a first in human phase 1 cell therapy trial, the 4 patients dosed within this first cohort received staggered treatment, in accordance with FDA guidance. Staggered treatment requires a follow up interval between the administration of the product to one patient and administration of the product to the next patient, essentially only allowing for sequential treatment of patients with an interval long enough to monitor for adverse events between the dosing of each patient. As the final patient of this first dose cohort successfully completes the DLT period, the study will begin to recruit patients for the next dose level which will introduce dual administration (ICT administration and intracranial intraventricular (ICV) administration). Annonce • Feb 01
Chimeric Therapeutics Appoints Cindy Elkins as Non-Executive Director Chimeric Therapeutics announced the appointment of Cindy Elkins as Non-Executive Director. Elkins experience includes her role as Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T technology focused on blood cancers. Her role evolved into Head of Global CAR T Patient Experience, responsible for connecting patients with their personalised medicine through world leading service and technology. Annonce • Jan 29
Chimeric Therapeutics Limited Appoints Dr. Yvonne Chen to Scientific Advisory Board Chimeric Therapeutics announced the appointment of Associate Professor Yvonne Chen to its Scientific Advisory Board. Dr. Chen is an Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles (UCLA). Annonce • Jan 16
Chimeric Therapeutics Limited has completed an IPO in the amount of AUD 35 million. Chimeric Therapeutics Limited has completed an IPO in the amount of AUD 35 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 175,000,000
Price\Range: AUD 0.2 